

Supplementary information

Table of content

Supplementary Table S1: Purity of the cell populations isolated from 11 SFV-infected individuals

Supplementary Figure S1: Alignment of SFV *bet* DNA coding sequence from 11 SFV-infected hunters.

Supplementary Figure S2: Alignment of SFV Bet amino-acid sequences from 11 SFV-infected hunters.

Supplementary Table S1: Purity of the cell populations isolated from 11 SFV-infected individuals

PBMC populations from the 11 SFV-infected individuals (sampled at two time points for BAD348, BAD468 and BAK74) were purified and stained with anti-CD3-FITC, anti-CD14-PE, anti-CD16-V450, anti-CD56-PC7, anti-CD8-APC, anti-CD4-APC-H7, and anti-CD20-PC5. LIVE/DEAD® Fixable Dead Cell Stain Kit was used to identify viable cells. Cells were gated by forward scatter and side scatter, and viable cells were selected based on live/dead labeling. CD4+ and CD8+ cells were defined in the CD3+ population. CD20+, CD14+, CD16+, and CD56+ cells were defined in the CD3- population. The purity of the isolated subset is indicated in red.

Individual	Cell subset	CD3+ CD4+ (% among live cells)	CD3+ CD8+ (% among live cells)	CD20+ (% among live cells)	CD14+ (% among live cells)	CD16+ or CD56+ (% among live cells)
AKO394	CD4+	94.7	2.6	0.0	0.1	2.1
	CD8+	1.1	81.3	0.0	0.1	18.1
	CD19+	3.9	3.6	76.2	0.7	4.3
	CD14+	4.5	5.3	0.2	58.5	21.0
	CD56+	0.7	4.7	0.2	0.5	91.2
BAD348	CD4+	90.0	1.4	0.1	0.1	3.5
	CD8+	3.2	88.5	0.1	0.9	4.8
	CD19+	2.6	1.9	70.6	1.3	2.1
	CD14+	2.6	1.4	2.2	71.1	16.3
	CD56+	4.2	30.3	0.4	3.2	51.7
BAD348	CD4+	96.7	1.2	0.0	1.6	0.6
	CD8+	2.2	94.1	0.3	1.6	1.7
	CD19+	0.8	0.9	88.3	5.7	2.2
	CD14+	5.8	2.6	0.6	87.8	4.4
	CD56+	3.1	30.6	2.5	9.8	47.1
BAD447	CD4+	93.2	2.2	0.0	0.0	2.3
	CD8+	1.5	96.8	0.6	0.3	0.9
	CD19+	2.2	4.6	85.4	1.0	0.8
	CD14+	5.6	8.0	1.1	50.9	28.3
	CD56+	2.5	7.3	2.1	22.9	59.7
BAD456	CD4+	90.8	2.5	0.0	0.0	5.0
	CD8+	2.6	77.6	1.5	1.1	18.6
	CD19+	1.8	9.1	77.1	1.3	3.1
	CD14+	5.4	4.9	1.2	60.5	25.9
	CD56+	2.6	17.2	0.9	4.4	71.3
BAD463	CD4+	96.5	1.0	0.0	1.7	0.8
	CD8+	5.9	91.3	1.0	2.3	3.6
	CD19+	2.8	4.8	80.4	7.9	1.9
	CD14+	8.7	2.9	0.5	82.1	4.4
	CD56+	3.6	16.2	0.4	21.8	50.5
BAD468	CD4+	96.4	0.4	0.1	0.2	1.3
	CD8+	1.1	84.1	0.3	0.5	11.5
	CD19+	3.1	2.6	94.9	0.9	0.9
	CD14+	2.0	0.7	2.1	78.5	9.5
	CD56+	2.6	8.2	1.3	18.7	62.6
04/09/2012	CD8+	1.1	84.1	0.3	0.5	11.5
	CD19+	3.1	2.6	94.9	0.9	0.9
	CD14+	2.0	0.7	2.1	78.5	9.5
	CD56+	2.6	8.2	1.3	18.7	62.6

BAD468	CD4+	95.0	1.0	0.0	0.0	2.4
15/11/2013	CD8+	2.2	87.0	0.8	0.2	9.7
	CD19+	2.6	3.6	80.9	2.6	9.5
	CD14+	6.8	3.4	1.2	54.4	28.3
	CD56+	2.2	6.1	8.6	11.2	68.7
	BAK177	CD4+	87.9	1.2	0.3	7.0
	CD8+	0.6	67.4	0.4	1.0	26.8
	CD19+	0.8	0.7	75.3	0.9	2.1
	CD14+	1.0	0.9	3.7	54.9	32.7
	CD56+	0.2	5.3	0.4	1.0	88.9
BAK232	CD4+	94.9	1.6	0.0	2.8	0.5
	CD8+	2.1	91.0	1.8	2.1	3.1
	CD19+	2.1	8.2	71.0	11.2	1.8
	CD14+	6.5	3.9	0.3	90.2	2.2
	CD56+	2.0	13.5	1.4	17.2	63.3
BAK55	CD4+	93.0	1.1	0.0	2.2	0.9
	CD8+	1.7	93.3	0.5	0.6	4.6
	CD19+	2.8	9.4	72.8	7.6	2.8
	CD14+	10.2	2.2	0.2	84.2	2.8
	CD56+	1.1	16.9	0.7	3.2	75.6
BAK74	CD4+	97.4	0.6	0.0	0.1	1.2
04/09/2012	CD8+	2.0	92.5	0.3	0.4	4.6
	CD19+	1.8	2.5	90.6	0.5	0.9
	CD14+	3.0	0.6	0.6	87.7	3.6
	CD56+	2.4	44.1	0.1	1.0	40.6
BAK74	CD4+	98.2	0.6	0.0	0.7	0.2
15/11/2013	CD8+	1.4	96.3	0.7	0.3	1.5
	CD19+	1.2	4.3	80.8	2.2	3.4
	CD14+	3.5	0.7	0.3	94.8	0.6
	CD56+	2.2	43.0	0.6	3.6	38.1
LOBAK2	CD4+	90.7	5.1	0.0	0.1	3.9
	CD8+	5.0	89.0	1.0	0.6	4.5
	CD19+	2.9	7.3	74.5	1.0	1.4
	CD14+	2.6	4.8	0.6	69.0	21.6
	CD56+	3.8	34.2	0.5	9.3	50.6
Mean (all individuals)	CD4+	94.0	1.6	0.1	0.7	2.3
	CD8+	2.3	87.9	0.7	0.8	8.1
	CD19+	2.2	4.5	79.9	3.2	2.7
	CD14+	4.9	3.0	1.1	73.2	14.4
	CD56+	2.4	19.8	1.4	9.1	61.4
Standard deviation (all individuals)	CD4+	3.1	1.2	0.1	1.0	2.0
	CD8+	1.5	8.1	0.5	0.7	7.9
	CD19+	0.9	2.9	7.5	3.5	2.2
	CD14+	2.6	2.2	1.0	15.2	11.7
	CD56+	1.1	14.0	2.2	8.0	16.4

AKO394	901	GCT	TAT	CAA	GTA	AAA	AGA	GAA	ACT	AAA	GCT	GCA	AAT	CTT	TCA	GAT	CAG	GCT	CTA	AGA	TGG	AAA	GCT	CTA	AAT	TTT	
BAD348	T	G.	C	
BAD447	G.	
BAD456	G.	
BAD463	G.	
BAD468	C	T	G.	C
BAK177	G.
BAK232	G.	
BAK55	G.	
BAK74	G.	
LOBAK2	T	G	C	

AKO394 1051 ATA GAA GCT TAT GGA CCT CAG AGA GGA AGT AGC GAG GAG AGG GTG TGG TGG AAA ACC ACT AGT ACC CTA GGG AAG
BAD348 .
BAD447 .
BAD456 .
BAD463 .
BAD468 .
BAK177 .
BAK232 .
BAK55 .
BAK74 .
LOBAK2 .

AKO394 1125 GAT GAA GAA TAT TAT AGA AGT GAG GGA GAA GAA GAA TGT TTC CCC AAC AGT CCT GCT CCT CAT CGC CGT ACT TGG
BAD348 . . G C C G G .
BAD447 . . G .
BAD456 . . G .
BAD463 . . G .
BAD468 . . G C C G G G .
BAK177 . . G .
BAK232 . . G .
BAK55 . . G C C G G G .
BAK74 . . G C C G G G .
LOBAK2 . . G C C G G G .

AKO394 1201 ACA GAG AGG CAT AAA GTC CTT GCC TTG TCA CCA TTC GCT ACT CCC TCT GAT ATC CAA AAG TGG GTT ACA AGG GCA
BAD348 A .
BAD447 .
BAD456 .
BAD463 .
BAD468 . . . A .
BAK177 .
BAK232 .
BAK55 .
BAK74 .
LOBAK2 A .

AKO394 1276 CTA CCT TAT AAG TGG AAA GTA ATC ACT TCA GAT GGG GAT GAT TAT GTT AGT ATG AGA ACA GTT AAA ACC TTG AAA
BAD348 C .
BAD447 .
BAD456 .
BAD463 .
BAD468 . . . C .
BAK177 .
BAK232 .
BAK55 C .
BAK74 .
LOBAK2 GC .

AKO394 1351 GAA CTA ACT CAA GAT GAA ATT AAA TGC CGA TGG GAA AAA GGC AAC TCT AAC CCT TTC TAT GAT TCA GGC AGT GAC
BAD348 .
BAD447 .
BAD456 .
BAD463 . . G .
BAD468 . . . C .
BAK177 .
BAK232 .
BAK55 .
BAK74 .
LOBAK2 .

AKO394 1426 TCA GAT GGC CCC TTT TAA
BAD348 A .
BAD447 .
BAD456 .
BAD463 A .
BAD468 . . . A .
BAK177 A .
BAK232 .
BAK55 A .
BAK74 .
LOBAK2 A .

Supplementary Figure S2: Alignment of SFV Bet amino-acid sequences from 11 SFV-infected hunters. Uncultured PBMC samples from 11 SFV-infected hunters accidentally infected by a *Gorilla gorilla* SFV strain were analyzed for the presence of SFV sequences. *bet* ORF-1 and ORF-2 were sequenced and translated. Dots represent identical residues.

AKO394	1	MDTYQEEES VASTS GVQDL QTL SEL VGP GAAGE GEDTLS DTEEVSKRSRKNT KRGAKMI TFHAYKEI EDKNP QNLKLHNWI PTPEEMI NKKVQNQD LGTILS	
BAD348	.	.	E. R. E.
BAD447	.	.	E.
BAD456	.	E.	D.
BAD463	.	E.	R.
BAD468	.	E.	R.
BAK177	.	E.	E.
BAK232	.	E.	D.
BAK55	.	E.	R.
BAK74	.	E.	R.
LOBAK2	.	E.	R.
AKO394	102	FGVKHLKGITSLGRNDPGRDPSAMS PVLPVVTPWPFSQDHYAPTL YGI LLQYYKYSQNNEKI PRVWQFTCLEDPSGKRYMGTRI WVPPLGQVTI QFYKNFVV	I.
BAD348	.	D.	I.
BAD447	.	.	.
BAD456	.	.	.
BAD463	.	D. . R. . .	K.
BAD468	.	D.	I.
BAK177	.	.	.
BAK232	.	.	.
BAK55	.	D.	I.
BAK74	.	D.	I.
LOBAK2	.	D.	I.
AKO394	205	LTVCQAVDP WANWFHGS EEE MYDI ESEPDVWCS AALCFKVI YEGNI NQKQEMKS WL CRLGHGHKGDGVS EFKRVDLFAMRKRKVNP YKDKGDP WL QYAYQVKR	G.
BAD348	.	I. . L. . .	G.
BAD447	.	.	G.
BAD456	.	.	G.
BAD463	.	I. . L. . .	G.
BAD468	.	.	G.
BAK177	.	.	G.
BAK232	.	.	G.
BAK55	.	I. . L. . .	G.
BAK74	.	I. . L. . .	G.
LOBAK2	.	I. . L. . .	G.
AKO394	307	ETKAANLSDQALRWKALNFHRALMCDLTNARI GE GHVANGYHMAIEAYGPQRGSSEERVWWKTTSTLGKDEEYYRSEGEEECFPNSPAPHRRTWTERHKVLA	I.
BAD348	.	G.	I.
BAD447	.	G.
BAD456	.	G.
BAD463	.	G.	A.
BAD468	.	G.
BAK177	.	G.
BAK232	.	G.	I.
BAK55	.	G.
BAK74	.	G.
LOBAK2	.	G.
AKO394	409	LSPFATPSDI QKWVTRALPYWKVI TS DGDDYVS MRTVKTLKELTQDEIKCRWEKGNSNPFYDSGS DS DGP F *	C.
BAD348	.	.	.
BAD447	.	.	.
BAD456	.	.	.
BAD463	.	.	.
BAD468	.	.	.
BAK177	.	.	.
BAK232	.	.	.
BAK55	.	.	.
BAK74	.	.	.
LOBAK2	.	C.